5324882022-07-012022-09-305324882022-09-305324882022-03-315324882022-04-012022-09-305324882022-07-012022-09-30in-bse-fin:OtherExpenses1Member5324882022-04-012022-09-30in-bse-fin:OtherExpenses1Member5324882022-07-012022-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15324882022-04-012022-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15324882022-07-012022-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15324882022-04-012022-09-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares532488DIVISLABNOTLISTEDINE361B01024Divi's Laboratories LimitedEquity2022-04-012023-03-312022-11-072022-10-28INRLakhsHalf yearlySingle segmentManufacture of Active Pharmaceutical Ingredients, intermediates and nutraceutical ingredients2022-11-0711:30:002022-11-0712:40:00trueCash Flow IndirectNot applicable2022-07-012022-09-30UnauditedConsolidated1854540000080080000019346200000817010000055400000-147920000023212000001700000857300000326750000013194000000615220000006152200000947700000268500000121620000004936000000000049360000003070000049667000004936000000049667000000530900000218.618.60018.618.61.The above Statement of consolidated unaudited financial results for the quarter and half year ended 30th September, 2022, Statement of consolidated unaudited assets and liabilities as at 30th September, 2022 and Statement of consolidated unaudited cash flows for the half year ended 30th September, 2022 (‘Consolidated Statements’) are prepared in accordance with Indian Accounting Standards (‘Ind AS”) prescribed under section 133 of the Companies Act 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The same were, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 7th November, 2022. The same also were subjected to “limited review” by the Auditors of the Company and their report contains no qualification. <BR> 2.The consolidated unaudited results include the financial results of Divi’s Laboratories Limited and its two subsidiaries Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG (Referred as the “Group”) <BR> 3 The Group is engaged in the manufacture of Active Pharmaceutical ingredients, intermediates, and nutraceutical ingredients and the same constitutes single reportable business segment as per Ind AS 108. <BR> 4. The Group does not have any discontinued operations and the profit for the period represents the profits from continuing operations only. <BR> 5.Forex gain included in Other Income and Loss included in Other Expenses for the respective periods is <BR> as given below: <BR> Rs. in lakhs <BR> Quarter ended Half Year ended Year ended <BR> 30.09.2022 30.06.2022 30.09.2021 30.09.2022 30.09.2021 31.03.2022 <BR> Forex gain/(loss) 3083 5640 (712) 8723 1252 4058 <BR> <BR> 2022-04-012022-09-30UnauditedConsolidated410906000001684700000427753000001595560000099600000-118930000047850000003000000169390000067623000002811010000014665200000014665200000230330000040580000027091000000119561000000000119561000007300000012029100000119561000000120291000000530900000245.0445.040045.0445.04Other expenses3267500000Other expenses676230000043215500000541910000009710000074530000006212000001366500000130200000655600000508840000002969930000001839670000025018000003086450000004340000051806400000279290000084298600000135182600000530900000120815900000121346800000121346800000024400000244000002971000004373100000469460000010000067499000004457000007195700000187170000041500000323000009141200000138358000001351826000001400000-141310000062067000000178300000200000-4370000064000000-123860000046800000-152430000001693900000003300000-219000000-16960000007544000000-2610000000043000000294960000017614800000000275660000001485820000000000000024651000000000000000000000007544000000-14823900000-16534600000000000001000000040000007964100000140000000-7969400000-96458000000-9645800000121476000002501800000Gain on Remeasurement of post-employment benefit obligations84000008400000Gain on Remeasurement of post-employment benefit obligations168000001680000019000003700000Exchange differences in translating the financial statements of foreign operations3070000030700000Exchange differences in translating the financial statements of foreign operations7390000073900000650000014000000